106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
ASCOMPM17123a
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
thoracic-cancer-guidelines. Copyright © 2018 by American Society of Clinical Oncolog y.
All rights reserved.
Source
Kindler HL, Ismaila N, Armato III SG, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen
M, Pass H, Rimner A, Rusch V, Sterman D, omas A, Hassan R. Treatment of Malignant
Pleural Mesothelioma: American Society of Clinical Oncolog y Clinical Practice Guideline.
J Clin Oncol. 2018 Jan 18; doi: 10.1200/JCO.2017.76.6394
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets,
frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki
Recommendation Grading
Type Evidence Quality
Strength of
Recommendation
EB Evidence-based H High Strong
I Intermediate Moderate
IC
Informal Consensus L Low Weak
Ins Insufficient
Abbreviations
2D, 2-dimensional; 3D, 3-dimensional; AJCC/UICC, American Joint Committee on Cancer/
Union for International Cancer Control; CE, carcinoembryonic antigen; CT, computed
tomography; EPCAM, epithelial cell adhesion molecule; EPD, extended pleurectomy/
decortication; EPP, extrapleural pneumonectomy; FDG, 18F-fluorodeoxyglucose; Gy,
Gray; IMRT, intensity-modulated radiation therapy; IV, intravenous; PET, positron
emission tomography; MPM, malignant pleural mesothelioma; PS, performance status; P/D,
pleurectomy/decortication; RECIST, Response Evaluation Criteria In Solid Tumors; TTF1,
transcription termination factor 1
